Standout Papers

Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic ... 2010 2026 2015 2020 1.0k
  1. Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity (2010)
    Scott M. Wilhelm, Jacques Dumas et al. International Journal of Cancer

Immediate Impact

5 by Nobel laureates 14 from Science/Nature 61 standout
Sub-graph 1 of 21

Citing Papers

MEG3 activates necroptosis in human neuron xenografts modeling Alzheimer’s disease
2023 StandoutScience
The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma
2022 Standout
1 intermediate paper

Works of Christopher A. Carter being referenced

Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
2010 Standout

Author Peers

Author Last Decade Papers Cites
Christopher A. Carter 940 498 789 503 15 2.3k
Susan L. Kelley 1304 314 877 260 26 3.4k
Gautam Maulik 1868 458 958 669 41 3.8k
Karl‐Heinz Thierauch 1012 405 887 362 33 2.5k
Ramasamy Jagadeeswaran 1118 236 593 684 46 2.2k
Jenny Tan 1288 243 639 357 46 2.5k
Alison Joly 1521 428 892 399 26 2.9k
Dennis B. Solt 1082 632 574 316 40 2.3k
Gordon Alton 1739 217 727 242 42 2.7k
Jeffrey S. Morris 668 445 1284 226 50 2.1k
Henning Schulze‐Bergkamen 1732 568 974 597 68 3.2k

All Works

Loading papers...

Rankless by CCL
2026